secwatch.observer — SEC 8-K summary
======================================

Issuer:     uniQure N.V. (QURE)
CIK:        0001590560
Form:       8-K
Filed at:   2024-11-21T23:59:59+00:00
Accession:  0001558370-24-015883
Event type: other_material
Sentiment:  neutral
Materiality: 0.40
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

uniQure doses first patient in Phase I/IIa trial of AMT-260 for refractory temporal lobe epilepsy
--------------------------------------------------------------------------------

- First patient dosed in GenTLE Phase I/IIa trial of AMT-260 for refractory mesial temporal lobe epilepsy (MTLE).
- AMT-260 uses AAV9 vector to deliver miRNAs that reduce GluK2 protein subunit expression, targeting seizure triggers.
- Trial includes two dose cohorts of six patients each across 10 U.S. sites; two more sites expected by end of 2024.
- CMO Walid Abi-Saab notes 1/3 of focal seizure patients lack effective treatment, highlighting potential for AMT-260.
- Preclinical studies showed dose-dependent seizure reduction; program updates expected in 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1590560/000155837024015883/0001558370-24-015883-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1590560/000155837024015883/qure-20241121x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-24-015883

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer